bl-b01d1
biokin pharma
['solid tumor', 'bl-b01d1', 'nsclc', 'sclc']
great responses of bl-b01d1-101 in patients with advanced, pretreated, metastatic solid tumors. it is a egfrxher3 bispecific antibody-drug conjugate (adc). responses were interesting in most tumors, especially nsclc. safety profile acceptable. #asco23 
Husband, Father. Medical Oncologist and Researcher focused in Thoracic Oncology.  Views are my own. Member of @latenightonc - the best podcast in oncology!